Dr. Chang summarizes key bladder cancer research from ASCO 2022
Sam S. Chang, MD, MBA, recaps 5 presentations from the 2022 American Society of Clinical Oncology Annual Meeting.
In this video, Sam S. Chang, MD, MBA, gives a recap of noteworthy bladder cancer abstracts presented at the 2022 American Society of Clinical Oncology Annual Meeting. Chang is the Patricia and Rodes Hart Professor of Urologic Surgery and the Chief Surgical Officer at Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
The following 5 abstracts are summarized:
Abstract 4504 (Pal et al): Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study
Abstract 4560 (Bellmunt et al): Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.
Abstract 4566 (Chen et al): Toripalimab (anti-PD-1) monotherapy as a second-line treatment for patients with metastatic urothelial carcinoma (POLARIS-03): Two-year survival update and biomarker analysis.
Abstract 4582 (Petrylak et al): Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.
Abstract LBA4505 (Jones et al): A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison
